CD274 and hepatocellular carcinoma: In this single-arm, phase 2 study, we evaluated the efficacy and safety of DEB-TACE combined with transarterial infusion of the PD-L1 inhibitor TQB2450 and oral administration of Anlotinib in patients with advanced HCC.